Insys Therapeutics (INSY) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
Insys Therapeutics Reports Second Quarter 2016 Results
August 3, 2016 6:50 AM EDTPHOENIX, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended June 30, 2016.
Highlights of and subsequent to the second quarter of 2016 include:
Total net revenue was $67.1 million, compared to $77.6 million for the second quarter of 2015;Net income totaled $4.4 million, or $0.06 per basic and $0.06 per diluted share, compared to net income of $7.3 million, or $0.10 per basic and $0.10 per diluted share, for the second quarter of 2015;Cash, cash equivalents and investments were $193.7 million as of June 30, 2016;... More